Retrospective analysis of real-world data to evaluate actionability of a comprehensive molecular profiling panel in solid tumor tissue samples (REALM study).

Date publication

septembre 2023

Journal

PloS one

Auteurs

Membres identifiés du Cancéropôle Est :
Dr SPAETH Dominique

Tous les auteurs :
Leroy K, Audigier Valette C, Alexandre J, Boussemart L, Chiesa J, Deldycke C, Gomez-Rocca C, Hollebecque A, Lehmann-Che J, Lemoine A, Mansard S, Medioni J, Monnet I, Mourah S, Pierret T, Spaëth D, Civet A, Galoin S, Italiano A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/37708140

Résumé

Considering the growing interest in matched cancer treatment, our aim was to evaluate the ability of a comprehensive genomic profiling (CGP) assay to propose at least one targeted therapy given an identified genomic alteration or signature (actionability), and to collect the treatment modifications based on the CGP test results in clinical practise for solid tumors.

Référence

PLoS One. 2023 09 14;18(9):e0291495